Conversely, the progression of NAFLD to hepatocellular carcinoma drastically decreased the estimated activity of CYP2B6 in hepatocellular carcinoma patients [71]. The gene discussed is CYP2B6; the disease is metabolic dysfunction-associated steatotic liver disease.